Hans-Georg Rammenee

from Wikipedia, the free encyclopedia
Hans-Georg Rammenee (2019)

Hans-Georg Rammenee (born April 12, 1953 in Tübingen ) is a German immunologist and researcher .

Live and act

From 1974 to 1980 he studied biology at the Eberhard-Karls-Universität Tübingen , where he did his doctorate with Jan Klein at the Max Planck Institute for Biology . As a post-doctoral student he was at the Scripps Institute in La Jolla and the Basel Institute for Immunology . He then went to the MPI for Biology in Tübingen, where he headed the Immunology Laboratory from 1987 to 1993. At the same time he was a professor at the University of Tübingen. From 1993 to 1996 he headed the Tumor Virus Immunology department at the German Cancer Research Center in Heidelbergand was a professor in Heidelberg. He then went back to the University of Tübingen, where he heads the Immunology Department at the Interfaculty Institute for Cell Biology.

Rammen is known for his research on the main histocompatibility complex and related peptides . In Tübingen he heads a research network on translational immunology.

He is involved in the development of immunotherapies against cancer, for example from 2010 in Tübingen in clinical tests for a vaccine specifically tailored to the respective patient, which is supposed to immunize them against their own cancer cells and is initially being tested in liver cancer. The starting point is the around 90 individually different genetic changes in the cancer cells, which are determined from a gene sequencing of the cancer cells and based on which synthetic peptides are then produced.

He is co-editor of Immunogenetics , Cellular and Molecular Life Science, and the European Journal of Immunology . He is on the scientific advisory board of immatics ( cancer immunotherapy ), which emerged from his department for immunology in Tübingen, as well as several other pharmaceutical research companies such as Synimmune and CureVac. He is one of the founders of Synimmune, which develops antibodies for cancer therapy, and is on the advisory board of CureVac , which develops drugs based on mRNA . In May 2020, he undertook a self-experiment with a Covid 19 vaccine developed by his working group.

Honors

Fonts

  • Editor with Christoph Huber , Thomas Wölfel, Cedrik Britten: Cancer immunotherapy standards and innovations . Deutscher Ärzteverlag, 2008
  • with T. Weinschenk, C. Gouttefangeas, S. Stevanovic: Towards patient-specific tumor antigen selection for vaccination . Immunol Rev. , Vol. 188, 2002, p. 164.
  • Peptides made to order . Immunity , Vol. 25, 2006, pp. 693-695
  • Survival of the fitters . Nature , Volume 419, 2002, pp. 443-445
  • News and Views: Immunology: Protein surgery . Nature, Volume 427, 2004, pp. 203-204
  • with K. Falk, O. Rötzschke, S. Stevanovic, G. Jung: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules . Nature Volume 351, 1990, pp. 290-296
  • with O. Rötzschke, K. Falk, K. Deres, H. Schild, M. Norda, J. Metzger, G. Jung: Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells . Nature, Vol. 348, 1990, pp. 252-254
  • with K. Falk, O. Rötzschke: Cellular peptide composition governed by major histocompatibility complex class I molecules . Nature, Vol. 348, 1990, pp. 248-251.
  • with Rötzschke, O., K. Falk, H.-J. Wallny, S. Faath: Characterization of naturally occurring minor histocompatibility peptides including H-4 and HY . Science , Vol. 249, 1990, pp. 283-287
  • with H.-J. Wallny: Identification of classical minor histocompatibility antigen as cell-derived peptide . Nature, Vol. 343, 1990, pp. 275-278
  • with K. Deres, H. Schild, K.-H. Wiesmüller, G. Jung: In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine . Nature Volume 342, 1989, pp. 561-564
  • with PJ Robinson, A. Crisanti, MJ Bevan: Restricted recognition of beta 2-microglobulin by cytotoxic T lymphocytes . Nature, Vol. 319, 1986, pp. 502-504.
  • with MJ Bevan: Evidence from in vitro studies that tolerance to self antigens is MHC-restricted . Nature, Volume 308, 1984, pp. 741-744

Individual evidence

  1. ↑ It existed until 1999
  2. ↑ Angelika Bachmann: With immunotherapy against liver cancer In: tagblatt.de of February 16, 2010
  3. ↑ Rammen Lake: ( page no longer available , search in web archives: Collaborative Research Center 685, Immunotherapy ) (PDF file)@1@ 2Template: Toter Link / www.immunology-tuebingen.de
  4. ↑ INPUT interview with Prof. Dr. Hans-Georg Rammenee - BioRegio STERN - Thinking ahead about the economy. In: bioregio-stern.de. April 4, 2011, accessed August 11, 2015 .
  5. ↑ Synimmune GmbH receives 2.5 million euros from the BMBF Go Bio competition (press release 434261). In: presseanzeiger.de. Retrieved August 11, 2015 .
  6. ↑ News & Opinion: Biotech Company Records. In: wiwo.de. Retrieved August 11, 2015 .
  7. ↑ The Impatient , Süddeutsche Zeitung, May 18, 2020.

Web links

personal data
SURNAME Rammen, Hans-Georg
BRIEF DESCRIPTION German immunologist
DATE OF BIRTH April 12, 1953
PLACE OF BIRTH Tübingen